Insulin resistance—a metabolic condition in which the body’s tissues fail to respond adequately to insulin—is a principal driving factor behind type 2 diabetes. The clinical implications of insulin resistance extend far beyond diabetes alone; it has long been associated with cardiovascular, renal, and hepatic diseases. However, quantitatively evaluating insulin resistance in a clinical setting remains a formidable challenge due to the complexity and invasiveness of direct measurement techniques. This limitation has historically obscured the broader epidemiological relationship between insulin resistance and various cancers.

The study led by Yuta Hiraike and collaborators addresses this knowledge gap through the development of AI-IR, an artificial intelligence-powered tool that integrates nine different biochemical and clinical markers routinely measured during health checkups. This multi-parametric approach allows AI-IR to generate a reliable insulin resistance score without recourse to complicated or costly assays. The model was rigorously trained and validated using anonymized medical datasets from independent cohorts in the United States and Taiwan, encompassing well over half a million individuals, ensuring robustness and generalizability across diverse populations.

Critically, AI-IR outperforms BMI, a conventional surrogate marker widely used to estimate metabolic risk, by reducing false positives and false negatives in predicting insulin resistance. BMI’s limitations stem from its inability to discriminate between metabolically healthy obese individuals and those with normal weight yet metabolically unhealthy profiles. By synthesizing diverse clinical data points into a single predictive metric, AI-IR offers a more nuanced and precise assessment that captures hidden insulin resistance which BMI alone cannot reveal.

Leveraging UK Biobank data, AI-IR enabled the researchers to conduct one of the largest population-scale analyses ever performed on the relationship between insulin resistance and cancer susceptibility. Their meta-analysis conclusively demonstrated that individuals predicted by AI-IR to have insulin resistance face significantly elevated risks for twelve distinct cancer types. This scale and rigor mark a pivotal milestone—providing the first definitive large-scale evidence that insulin resistance is not merely a correlative but a meaningful risk factor for a broad spectrum of malignancies.

Understanding the biological underpinnings of this link between insulin resistance and cancer implicates chronic hyperinsulinemia and systemic inflammation as potential mechanistic pathways. Insulin resistance results in elevated circulating insulin levels which, aside from regulating glucose metabolism, can function as a mitogen promoting cellular proliferation in various tissues. Additionally, the pro-inflammatory milieu found in insulin-resistant states fosters an environment conducive to oncogenesis, thereby elevating cancer risks.

One of the compelling aspects of this research is its translational potential for preventive medicine. Because AI-IR relies on parameters commonly included in routine health screenings, its implementation can be seamlessly integrated into existing healthcare infrastructures. Identifying individuals with subclinical insulin resistance enables targeted surveillance and early interventions, such as lifestyle modifications or pharmacological treatments, aiming to mitigate the downstream risks of diabetes, cardiovascular disease, and notably, cancer.

The development process of AI-IR also confronted skepticism within the scientific community, particularly around its ability to replicate the predictive accuracy of direct insulin resistance measurements which are impractical at scale. Yet, AI-IR demonstrated consistently strong performance across multiple independent validation datasets, underscoring its viability as an alternative evaluative tool for clinical and epidemiological applications worldwide.

Moreover, the team is actively expanding their research to dissect the genetic determinants that influence individual susceptibility to insulin resistance and related cancer risks. By integrating large-scale genomic data with molecular biology insights, the researchers aim to unravel personalized risk profiles and therapeutic targets, propelling the field toward precision medicine strategies designed to combat these interconnected diseases more effectively.

This study’s implications also reverberate through public health domains, highlighting the necessity for comprehensive metabolic health assessments beyond BMI-centric paradigms. With obesity rates climbing globally and cancer incidence continuing to grow, AI-based innovations like AI-IR may become critical pillars in early detection frameworks, optimizing healthcare resource allocation and improving patient prognoses through preemptive action.

In summary, the introduction of AI-IR epitomizes the transformative power of artificial intelligence in medical research, bridging the gap between complex metabolic phenotypes and disease outcomes. It offers a scalable, accessible, and scientifically rigorous approach to identifying insulin resistance, illuminating its multifaceted role in carcinogenesis and heralding a new era of integrated disease risk prediction that could significantly affect cancer epidemiology and prevention strategies worldwide.

Subject of Research: People

Article Title: Machine learning-predicted insulin resistance is a risk factor for 12 types of cancer

News Publication Date: 16-Feb-2026

Web References:
https://doi.org/10.1038/s41467-026-68355-x

References:
Chia-Lin Lee, Tomohide Yamada, Wei-Ju Liu, Kazuo Hara, Toshimasa Yamauchi, Shintaro Yanagimoto & Yuta Hiraike, “Machine learning-predicted insulin resistance is a risk factor for 12 types of cancer”, Nature Communications

Image Credits:
©2026 Hiraike et al. CC-BY-ND

Keywords:
Insulin resistance, AI-IR, machine learning, cancer risk, diabetes, metabolic health, BMI, artificial intelligence, epidemiology, predictive modeling, population health, precision medicine

Skin autofluorescence is essentially a proxy for the accumulation of AGEs, compounds formed through a non-enzymatic reaction between sugars and proteins or lipids. These AGEs alter tissue structure and cellular function, promoting inflammation and oxidative stress. While the relationship between AGEs and chronic diseases like type 2 diabetes (T2D) and cardiovascular disease (CVD) has been extensively documented, their involvement in carcinogenesis remains an emergent field of inquiry. This study, led by Boersma et al., systematically explores whether elevated SAF correlates with an increased incidence of cancer over a long-term follow-up.

The Lifelines Cohort Study, a large population-based cohort from the Northern Netherlands, served as the fertile ground for this investigation. The study’s expansive design involved nearly 78,000 participants, who were initially screened between 2006 and 2013 and followed for a median duration of 11.5 years. Importantly, all participants were cancer-free at baseline, thereby allowing the researchers to assess new cancer development prospectively. Additionally, a subgroup of participants diagnosed with T2D was included to provide insight into whether pre-existing metabolic dysfunction alters the SAF-cancer association.

During the observational period, the incidence of cancer varied markedly among different groups. Among participants without diabetes, cumulative cancer rates reached 10.7% in males and 12.5% in females. In contrast, those living with T2D evidenced significantly higher cancer incidences—23.6% in males and 20.2% in females—consistent with earlier evidence that diabetes confers an elevated risk for several malignancies. However, what distinguishes this research is its focus on SAF as a predictive metric, independent of traditional risk factors.

Cox proportional hazards models revealed a robust association between SAF levels and subsequent cancer diagnosis. Unadjusted analyses showed that higher SAF predicted more than double the hazard of cancer development across the entire cohort, with a hazard ratio (HR) of approximately 2.36. Notably, this relationship was more pronounced in men, who exhibited a hazard ratio exceeding 3.0. Even after rigorous adjustments for confounders—such as age, sex, body mass index, waist circumference, smoking history quantified in pack-years, presence of diabetes, and metabolic syndrome—the link between increased SAF and cancer risk persisted, albeit with a more modest HR of 1.11.

Such resilience of the SAF association following multifaceted adjustments underscores its potential as an independent biomarker for cancer risk. Sensitivity analyses excluding skin cancers and cancers diagnosed within two years of baseline further strengthened the findings, indicating that heightened SAF precedes cancer onset rather than reflecting existing disease. These analytical layers cumulatively suggest that SAF measurement might provide clinicians with a non-invasive window into patients’ oncogenic milieu well before malignancy manifests clinically.

The study also disentangled cancer type-specific relationships with SAF. Particularly, cancers of the lung, oesophagus, and urinary tract demonstrated the strongest associations, all achieving high statistical significance. Other malignancies, including ovarian, female genital tract, and liver cancer, yielded suggestive but less potent correlations. This site-specific pattern potentially reflects differential AGE accumulation or diverse tissue susceptibilities, inviting further exploration into organ-specific pathophysiological pathways linking glycation to carcinogenesis.

When focusing on participants with type 2 diabetes, elevated SAF similarly correlated with increased cancer risk in unadjusted models. Nevertheless, this association lost statistical significance once age and sex were accounted for, and notably after full adjustment for confounders, indicating a more complex interplay in this subgroup. It is plausible that diabetes-linked metabolic derangements overshadow the predictive value of SAF in these patients, or that SAF simply reflects a convergence of risk factors rather than exerting an independent effect.

Mechanistically, the connection between AGEs, reflected via SAF, and cancer development may center on the chronic pro-inflammatory state induced by AGE accumulation. AGEs can crosslink extracellular matrix proteins, impair cellular repair mechanisms, and activate receptors such as RAGE (receptor for advanced glycation end-products), triggering intracellular signaling cascades that promote tumorigenesis. Moreover, oxidative stress fueled by AGEs may induce DNA damage, genomic instability, and dysregulated cell proliferation, all hallmarks of cancer biology.

From a clinical standpoint, the emergence of SAF as a potential biomarker heralds significant innovation in oncology screening protocols. Unlike invasive tissue biopsies or expensive imaging studies, SAF measurement uses non-ionizing technology and can be performed swiftly in outpatient settings. If future validations corroborate these findings, SAF could be integrated into risk prediction algorithms, particularly among populations at heightened risk due to metabolic disorders or age, enabling targeted surveillance and early interventions.

Nonetheless, several questions remain before SAF can be adopted in oncologic practice. The current study, though robust, is observational and cannot definitively establish causality. Additionally, the moderate hazard ratios post-adjustment signal that SAF alone might best be used as part of a multimodal risk assessment rather than a standalone predictor. Moreover, elucidating the biological mechanisms that underpin SAF’s association with specific cancer types will be critical to developing tailored preventive strategies.

Importantly, the study leveraged comprehensive pathology data from the Dutch Nationwide Pathology Databank (PALGA) to accurately classify incident cancers, enhancing the reliability of outcome ascertainment. This data linkage, combined with an extensive follow-up period, strengthens the evidence base for SAF’s predictive value. The study’s geographical and demographic context—predominantly Northern European populations—also warrants further research in more ethnically and environmentally diverse cohorts to evaluate generalizability.

In summary, this pioneering investigation by Boersma and colleagues positions skin autofluorescence as a promising, non-invasive biomarker related to future cancer risk across a broad population. While SAF is already established in monitoring diabetes and cardiovascular disease risk, its extension into oncology heralds a new frontier linking metabolic health to malignancy prediction. As science advances towards precision medicine, tools like SAF measurement may empower clinicians to identify at-risk individuals earlier and tailor prevention strategies more effectively.

Future research directions include prospective interventional studies to determine whether reducing AGE accumulation can mitigate cancer risk, and whether SAF-guided screening translates into improved clinical outcomes. Additionally, integrating SAF with genomic, proteomic, and metabolomic data could refine risk stratification models, uncover mechanistic insights, and reveal novel therapeutic targets. These efforts will be essential to fully harness the potential of SAF in the fight against cancer.

The revelation that a simple measure of skin fluorescence can forecast complex disease states long before clinical symptoms arise exemplifies the transformative power of biomarker science. As this field matures, widespread SAF screening could become routine, reshaping how medicine anticipates and intercepts cancer development at its earliest phases.

Subject of Research: The association between skin autofluorescence (SAF)—a marker of advanced glycation end-product accumulation—and future cancer risk in a large population-based cohort.

Article Title: Increased skin autofluorescence predicts future cancer development

Article References:
Boersma, H.E., Sidorenkov, G., Smit, A.J. et al. Increased skin autofluorescence predicts future cancer development. BMC Cancer 25, 1375 (2025). https://doi.org/10.1186/s12885-025-14801-w

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14801-w

Type 2 diabetes, a metabolic disorder characterized by insulin resistance and chronic hyperglycemia, affects over 120 million people in the United States alone, many of whom face an elevated risk of cancer mortality. While epidemiological data have long suggested that diabetic patients experience poorer breast cancer outcomes, the biological underpinnings remained obscured until now. Dr. Denis and his team employed cutting-edge patient-derived organoid cultures, a 3D tumor modeling technique that preserves the native architecture and immune microenvironment of breast cancers, to dissect the molecular dialogue between diabetic plasma exosomes and tumor-infiltrating immune cells.

The study meticulously isolated exosomes from the blood plasma of individuals with type 2 diabetes and non-diabetic controls, all devoid of known cancer, to tease apart the influence of metabolic disease on tumor biology independent of tumor-derived factors. These exosomes were then applied to patient-derived breast tumor organoids, enabling researchers to investigate functional changes within the tumor milieu at single-cell resolution using advanced RNA sequencing technologies. This innovative approach enabled unprecedented insight into how metabolic dysregulation might pivotally impair intrinsic immune surveillance mechanisms.

Results demonstrated that exosomes from diabetic donors induce a reprogramming of immune cells within tumor tissues, fundamentally weakening their ability to mount effective anti-cancer responses. Immune effector populations, including cytotoxic T lymphocytes and natural killer cells, exhibited suppressed activity and altered gene expression profiles after exposure to diabetic exosomes. Correspondingly, organoids treated with these exosomes displayed enhanced tumor cell proliferation, indicative of accelerated cancer aggression and potential for metastasis.

This immune suppression appears to be mediated by specific molecular cargo within the diabetic exosomes, such as microRNAs and proteins, which modulate signaling pathways crucial for immune cell activation and tumor surveillance. By dampening the tumor’s immune microenvironment, these exosomes effectively create a permissive niche where cancer cells evade immunological destruction, a phenomenon that may partly explain the diminished efficacy of immunotherapies observed in diabetic breast cancer patients.

The significance of this research is amplified by the preservation of the tumor’s native immune context in organoid cultures, making the findings highly translatable to clinical scenarios. Such patient-specific models are a leap forward from traditional cell lines, which often lack the complex interplay of immune and stromal cells critical for comprehensive cancer biology understanding. This model thus provides an invaluable platform for testing therapeutic interventions aimed at counteracting immune suppression induced by metabolic factors.

Moreover, the findings suggest the urgent need to stratify cancer patients based on metabolic health, particularly diabetes status, when considering immunotherapeutic regimens. The current one-size-fits-all approach in oncology overlooks how systemic diseases like diabetes reshape tumor-immune interactions, possibly undercutting the success of cutting-edge treatments. Tailoring therapies to restore immune competence in diabetic patients may not only improve response rates but also curb cancer progression more effectively.

Recognizing the wider implications, the research team envisions expanding the investigation into other solid tumors where type 2 diabetes is prevalent, such as pancreatic and colorectal cancers. Given the centrality of immune evasion in cancer progression, it is plausible that similar exosome-mediated immune modulation occurs across diverse cancer types, further entrenching metabolic disease as a critical factor in oncology.

Discussing the complex pathophysiology, Dr. Denis emphasized that diabetes-induced changes in exosome content likely arise from metabolic stress and inflammation characteristic of diabetic physiology. These altered exosomes represent a systemic conduit by which metabolic disease exerts long-range effects on distant tissues, in this case, transforming the tumor microenvironment. This insight opens new avenues for biomarker discovery, where circulating exosomes could serve as predictive indicators of tumor behavior and patient prognosis.

Technologically, the use of single-cell RNA sequencing in this context provides granular data on heterogeneous immune cell populations within tumors, revealing nuanced shifts in phenotypes and functional states orchestrated by diabetic exosomes. Such resolution is crucial for identifying targetable pathways underpinning immune suppression and for the design of precision immunotherapies.

Importantly, the study received funding support from notable National Institutes of Health grants, underscoring the critical role of federal investment in pioneering medical research. Collaborations between clinical oncology, cellular biology, and metabolic disease experts were instrumental in achieving these insights, highlighting the importance of interdisciplinary approaches in tackling complex biomedical problems.

In sum, this research marks a paradigm shift in understanding how metabolic disorders like type 2 diabetes intricately alter cancer biology beyond mere epidemiological associations. It underscores the imperative to consider the systemic metabolic state in cancer treatment planning and opens promising paths toward developing personalized, metabolism-informed therapeutic strategies that could improve survival and quality of life for millions of cancer patients globally.

Subject of Research: Human tissue samples

Article Title: Plasma exosomes from individuals with type 2 diabetes drive breast cancer aggression in patient-derived organoids

News Publication Date: 26-Aug-2025

Keywords: Breast cancer cell lines, Diabetes